The Fijian government has cleared a new bill that would pave the way to private ownership of Fijian surf areas - including ...

If Ryan Callinan gave me music recommendations, I’d save them to a playlist in a heartbeat. Over the years I’ve found the music he layers over his edits to be quite enjoyable. Whether it’s “You Got It ...

Cloudbreak Pharma, Inc. ( ($HK:2592) ) has provided an announcement. Cloudbreak Pharma, Inc. has announced a new board of directors effective from ...

The ride out to Cloudbreak was calm. Barely a flatulence of wind. Sun shining. A few latte clouds lingered over Tavarua across the horizon of the South Pacific. “Are we on?” The boat wondered. We had ...

Come for the waves, stay because, well, because it’s paradise. Nowhere else in the world embodies the surf ideal more than the fantasy island that is Tavarua, Fiji. Kelly Slater calls it “nirvana.” ...

As 11-time world champ Kelly Slater astutely points out in the new issue of SURFER, from two feet to 20, Cloudbreak is unequivocally one of the best surf breaks in the world. Located in the Mamanuca ...

In June 2012, during the WSL’s Fiji Pro waiting period, the charts turned dark purple and the horizon went black. After running a few heats at XL Cloudbreak on the biggest day of the swell, the WSL ...

The acquisition was made in concert with the company's strategic rebrand to Equiti. Together, these initiatives further enhance Equiti's service offerings and solidify its position as a leading ...

Cloudbreak Discovery Plc engages in the natural resource project generation and royalty business worldwide. The company primarily focuses on exploring for mineral properties and petroleum resources.

LOS ANGELES & COLUMBUS, Ohio--(BUSINESS WIRE)--Cloudbreak Health, LLC (“Cloudbreak”), a leading telehealth and video remote interpretation solutions provider, and Extended Care LLC, a leading ...

Cidara Therapeutics is leveraging its Cloudbreak platform to develop CD388 for universal influenza prophylaxis. Fortunately, they recently enrolled 5,000 subjects in its Phase 2b trial to assess CD388 ...